Inhaled epinephrine for systemic allergic reactions during allergy testing, immunotherapy, or oral challenges

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1b, open-label, multi-center exploratory study will enroll up to 100 patients who experience a Grade 2 or higher systemic allergic reaction during planned allergy testing, SCIT, OIT, or oral challenges and who are not eligible for the GHL-101 protocol. Enrolled participants will receive inhaled epinephrine at the time of an eligible systemic allergic reaction and will be observed for safety and clinical effects. The maximum participation period for each subject is approximately one week, and dosing and monitoring procedures will be recorded at study visits. The study is intended to characterize tolerability, immediate clinical response, and feasibility of the inhaled route in this acute setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Males or females, aged ≥ 12 years with known or suspected allergen sensitivity who can also have a clinical history of immunoglobulin E (IgE)-mediated allergy, including a documented sensitivity to allergens (i.e., positive skin prick test, or positive in vitro serum IgE).
2. Have undergone either a) allergy testing for suspected sensitivity/allergy, b) future oral challenge (food and/or drug) or future OIT to treat existing allergies or c) SCIT AND experienced a SAR Grade 2 or higher, following allergy testing, SCIT, or oral challenges (food and/or drug) for future OIT, and deemed eligible for enrollment by the Principal Investigator.
3. For females of child-bearing potential, not pregnant or lactating, willing to use an acceptable contraception\* method between Screening and End-of-Study Visits.

Exclusion Criteria:

1. Known reaction or sensitivity to epinephrine or any of the ingredients of inhaled epinephrine.
2. Known history or presence of clinically disease/condition that could confound the results of the study or place the subject at undue or additional risk per the judgment of the Investigator.
3. Abnormal vital signs at screening (i.e., systolic blood pressure: \< 90 or \>140 mmHg, diastolic blood pressure: \< 40 or \> 90 mmHg or, heart rate: \< 45 or \> 100 bpm), respiration rate \< 8 or \> 20 resp./min.
4. Females who are pregnant, plan to become pregnant or lactating.
5. Participation in another clinical study involving an investigational drug within 30 days prior to screening, an investigational biologic within 60 days prior to screening, or current/planned participation in another interventional study during this study.
6. Previous treatment in this study.
7. Any other reason that, in the opinion of the Investigator, is likely to unfavorably alter subject risk-benefit, confound results, or make it difficult for the subject to fully comply with study requirements.

Where it's running

• Kokua Pharma Inc.
  Richmond, British Columbia, Canada Recruiting

Study contacts

• Principal investigator: George H. Luciuk, MD — Kokua Pharma Inc.
• Study coordinator: George H. Luciuk, MD
• Email: gh.luciuk@dr.com
• Phone: 1-604-270-7801

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• What the Mayo Clinic is learning from blood clot tests in allergic reactions

  This study tests whether real-time blood clotting markers can help understand and predict the severity of allergic reactions and anaphylaxis in patients 12 and older.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07905911

• Comparing intraosseous and infiltration anesthesia for children with MIH

  We will test whether intraosseous or infiltration anesthesia delivered with a computer-assisted device better reduces pain and anxiety during fillings of permanent first molars in children with MIH.

  Recruiting Ankara Yildirim Beyazıt University · Ankara · NCT07352813

• Steroids for allergic reactions to food in children

  This study will test whether giving steroids in addition to adrenaline and antihistamines helps children who have allergic reactions during supervised food challenges.

  Recruiting at 2 sites Phase 4 University Children's Hospital, Zurich · Basel, Basel and 1 other locations · NCT07341776

• Different forms of IgE in health and disease.

  We will test whether different forms of IgE in the blood differ between healthy adults and people with allergies, chronic spontaneous urticaria, recent anaphylaxis, mastocytosis, hereditary alpha tryptasemia, X‑linked agammaglobulinemia, or those undergoing venom/medication desensitization.

  Recruiting KU Leuven · Leuven, Vlaams-Brabant · NCT07328178

• Child Life Services to Help Kids During Skin Prick Testing

  This study tests whether child life services can ease pain and anxiety for children and reduce caregiver stress during skin prick testing.

  Recruiting Children's Hospital of Fudan University · Shanghai · NCT07319273

• Finding causes of allergic reactions during and after surgery

  This project tests whether measuring tryptase levels and doing skin tests can find the cause of suspected allergic reactions during or after surgery for patients aged 2 and older.

  Recruiting at 5 sites Peking University First Hospital · Beijing, Beijing Municipality and 5 other locations · NCT06793163

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.